Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 101 to 125 of 335

Guidance and quality standards awaiting development
Title	Type
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]	Technology appraisal guidance
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]	Technology appraisal guidance
Edaravone for treating amyotrophic lateral sclerosis TS ID 11869	Technology appraisal guidance
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046	Technology appraisal guidance
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847	Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]	Technology appraisal guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]	Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment ID 6463	Technology appraisal guidance
Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015	Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037	Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]	Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]	Technology appraisal guidance
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]	Technology appraisal guidance
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction TS ID 12051	Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]	Technology appraisal guidance
Galcanezumab for migraine TS ID 10663	Technology appraisal guidance
Gambling	Quality standard
Gantenerumab for treating early Alzheimer's disease TS ID 10668	Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]	Technology appraisal guidance
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312	Technology appraisal guidance
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [TS ID 12050]	Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]	Technology appraisal guidance
Gout	Quality standard
Govorestat for treating classic galactosemia in people 2 to 65 years TS ID 12071	Technology appraisal guidance

Results per page

10
25
50
All